Elijah-Co

“...a wonderfully crafted mystery-thriller…” — Ronald D. Demmans, Author of Eminent Domain Dr. Lars Sorenson, an ambitious young oncologist, is crushed when the promised funding for his cancer center is withdrawn. An obsessively secretive company, Elijah-Co, appears as a white knight—but with its own agenda. Lars can conduct human trials on Elijah-Co’s new cancer-killing drugs, but only if he agrees to perform a shadow study of one of them, EJ 181. Animal data suggests that this drug can reverse the aging process. Lars must prove its effectiveness in humans by conducting a clandestine trial. His research takes on greater urgency when he discovers that his wife’s mysterious illness may be cured by EJ 181. Half-truths and lies dot the landscape as Lars pursues Elijah-Co’s true goal of proving that EJ 181 can endow amortality. Fiction is reality on steroids, and the novel Elijah-Co delivers that. Science fiction, however, needs to have deep roots in reality—the science must be believable. Dan Luedke’s experience with clinical cancer research provides the expertise for a credible scientific platform as Elijah-Co pursues age reversal and amortality.